Estrogen-related Receptor Gamma (ERRγ; NR3B3)
These nuclear receptor assay systems utilize proprietary non-human mammalian cells engineered to provide high-level expression of a hybrid form of Human ERRγ (also known as NR3B3). Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRγ activity in treated cells. As is true in vivo, these reporter cells express ERRγ in a constitutive state of high-level activity in the putative absence of bound ligand. Interestingly, the ligand binding domain of ERRγ may be occupied by a ligand that produces further elevation of the receptor’s constitutive activity (an agonist response). Alternatively, ERRγ may have ligand-binding interactions that results in the loss of constitutive active (an inverse-agonist response). Therefore, the principle application of this assay system is in the screening of test samples to quantify the agonist or inverse-agonist activities that they may exert against human ERRγ.
For more information on ERRγ, visit the Nuclear Receptor Resource.
Kits are offered in different assay formats to accommodate researchers’ needs: 3 x 32, 1 x 96, and 1 x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, an inverse-agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.
ERRγ Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.
The principle application of this assay product is in the screening of test samples to quantify inverse-agonist activities that they may exert against human ERRγ. This kit product is an all-inclusive assay system that includes, in addition to ERRγ Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference inverse-agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.
|Product Family||Product Number||Product Description|
|IB0802 ERRγ (NR3B3)||IB08021-32||Human ERRγ Reporter Assay System, 3 x 32 assays in 96-well format|
|IB08021||Human ERRγ Reporter Assay System, 1 x 96-well format assays|
Service Assays: Human
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters. To initiate a Service Study, download and complete all fields of the Excel worksheet “Service Work Order" then submit the electronic file to INDIGO Customer Service.
New Assay to Test Target Compounds for Anti-Obesity Therapeutics State College, PA (September 18, 2014) – INDIGO Biosciences, a leading provider of nuclear receptor products and services announced today that it has released a new Human Estrogen-related Orphan Receptor Gamma (NR3B3; ERRγ) Assay System. Three different assay kits are available. ERRg is naturally expressed in